Funds will Advance Company’s Immuno-Oncology Small Molecule and Antibody Programs Burlingame, CA, September 29, 2015 – Corvus Pharmaceuticals, a private clinical-stage biopharmaceutical company focused on the development of novel agents targeting the immune system to treat patients with cancer, today announced that it closed a $75 million Series B financing. The transaction was led by …

Read More

Releasefaa9345b-168e-47b5-8d3e-2b4b4a581492_2150864.pdf Cranbury, NJ – July 27, 2015 — Oncobiologics, Inc.,announced the closing of a $31 million financing. Proceeds will be used to support continued development and expansion of the company’s proprietary BioSymphony™ biosimilar platform and advancement of its preclinical and clinical programs. The investment round was led by new investor, Perceptive Advisors. Participating new investors …

Read More